ClinicalTrials.gg
CompletedNCT03009981Updated Nov 9, 2026Results posted

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

A Phase 3 interventional study of Apalutamide and LHRH Analogue in Prostate Cancer, sponsored by Alliance Foundation Trials, LLC.. Completed at 69 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Alliance Foundation Trials, LLC. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
503
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
11th of 70
503 · median 81
Started
2017
with 8 others
Phase 3
16 of 70
2 open now
Registered
20th of 70
by date

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 11th largest by enrollment, is one of 9 that started in 2017, is one of 16 in phase 3, and was the 20th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.

Read the detailed description

Patients will be stratified by PSA doubling time (\< 3 months vs. 3-9 months) and randomized in 1:1:1 fashion to one of three treatment arms: (1) Control arm consisting of LHRH analogue monotherapy (degarelix or leuprolide), (2) Experimental arm consisting of apalutamide in combination with LHRH analogue, and (3) Experimental arm consisting of apalutamide, abiraterone acetate + prednisone, and LHRH analogue. Patients will be treated for a maximum duration of 52 weeks and then enter follow up phase until the time of PSA progression, development of metastasis, or patient withdrawal from study, whichever occurs first. Patients with PSA progression will be followed long term until the development of castration resistance, first metastasis, and death.

The primary endpoint of the study is PSA progression-free survival in the intent-to-treat patient population. PSA progression during the 52-week treatment period is defined as a rising PSA confirmed on repeat measurement, and at least 25% and 2 ng/mL above nadir or baseline, whichever is lower. PSA progression during follow up defined as PSA > 0.2 ng/mL confirmed by repeat measurement at least 2 weeks later. Secondary study endpoints include PSA progression-free survival in testosterone-evaluable population, 36-month PSA progression-free survival rate in both intent-to-treat and testosterone-evaluable populations, time to testosterone recovery, time to castration resistance, metastasis-free survival, quality of life, and safety. Each experimental arm will be compared against the control arm in pair-wise fashion. The study is not powered to detect differences in primary or secondary endpoints between the two experimental arms.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • PSA
  • Degarelix
  • Apalutamide
  • Abiraterone Acetate
  • Radical Prostatectomy
  • Bicalutamide
  • Leuprolide
  • Lupron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed prostate adenocarcinoma
  • Prior radical prostatectomy
  • Biochemically recurrent prostate cancer with PSA doubling time ≤ 9 months at the time of study entry. Calculation of PSA doubling time should include the use of all available PSA values obtained within past 6-12 months prior to randomization, with a minimum of 3 values separated by at least 2 weeks apart. PSA values obtained prior to therapeutic interventions (e.g. salvage radiation) will be excluded. PSA doubling time to be estimated using Memorial Sloan Kettering Cancer Center online calculator (https://www.mskcc.org/nomograms/prostate/psa-doubling-time)
  • Prior or salvage radiation or not a candidate for radiation based upon clinical assessment of disease characteristics and patient co-morbidities.
  • Screening PSA > 0.5 ng/mL
  • No definitive evidence of on screening CT or MRI of abdomen/pelvis and radionuclide whole body bone scan per the judgment of the investigator. Abdominal and/or pelvic lymph nodes measuring 2 cm or less in short axis diameter are allowed. Lesions identified on other imaging modalities (e.g. PSMA or choline PET) that are not visualized on CT and/or MRI or radionuclide bone scan are allowed. Equivocal lesions on bone scan should be followed up with additional imaging as clinically indicated.
  • Screening serum testosterone > 150 ng/dL
  • (ECOG) Performance Status grade 0 or 1
  • Age ≥ 18 years
  • Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to cycle 1 day 1
  • Agrees to use a condom (even men with vasectomies) and another effective method of if he is having sex with a woman of or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.
  • Adequate organ function as defined by the following laboratory values at screening:

    • Serum (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) \< 2.5 x (ULN)
    • Total serum ≤1.5 x ULN. In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤1.5 × ULN, subject may be eligible)
    • Serum potassium ≥ 3.5 mmol/L. Supplementation and re-screening is allowed.
    • Estimated > 45 ml/min using Cockroft-Gault equation
    • ≥ 100,000/microliter independent of transfusion and/or growth factors within 3 months prior to randomization
    • ≥ 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to randomization
    • Serum albumin ≥ 3.0 g/dL

Exclusion criteria

Exclusion Criteria:

  • Prior androgen deprivation therapy and/or first generation anti-androgen (e.g. bicalutamide, nilutamide, flutamide) for biochemically recurrent prostate cancer. Prior ADT and/or first generation anti-androgen in the (neo) and/or salvage setting before, during, and/or following radiation or surgery is allowed provided last effective dose of ADT and/or first-generation anti-androgen is > 9 months prior to date of randomization and total duration of prior therapy is ≤ 36 months.
  • Prior treatment with CYP17 inhibitor (e.g. ketoconazole, abiraterone acetate, galeterone) or second generation androgen receptor antagonist including apalutamide or enzalutamide
  • Prior chemotherapy for prostate cancer except if administered in neoadjuvant or adjuvant setting
  • Use of 5-alpha reductase inhibitor within 42 days prior to cycle 1 day 1
  • Use of agent within 28 days prior to randomization
  • Use of other prohibited medications within 7 days prior to cycle 1 day 1 on study (Arms B and C only)
  • Prior bilateral orchiectomy
  • Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)
  • Uncontrolled hypertension
  • Gastrointestinal disorder affecting absorption or the ability to swallow tablets
  • Baseline severe hepatic impairment ( Class B \& C)
  • Intercurrent illness that is not controlled such as active infection, psychiatric illness/social situations that would limit compliance with study requirements
  • Any chronic medical condition requiring a higher dose of than equivalent of 5 mg prednisone/prednisolone once daily
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
503 participants (actual)

Study arms

  • Active comparator
    Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide

    Patients will receive degarelix OR leuprolide with bicalutamide.

    Drug: LHRH Analogue

  • Experimental
    Arm B: Degarelix/Apalutamide

    Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.

    Drug: Apalutamide · Drug: LHRH Analogue

  • Experimental
    Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone

    Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.

    Drug: Apalutamide · Drug: LHRH Analogue · Drug: Abiraterone Acetate · Drug: Prednisone

Interventions

  • Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.

    Also known as: Erleada

  • DrugLHRH Analogue

    Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide. Degarelix: Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles. Leuprolide: Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion: 1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide. OR: 2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1.

    Also known as: Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide

  • Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.

    Also known as: Zytiga

  • Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.

    Also known as: Deltasone

06

What researchers measure

Primary outcomes

  1. PSA Progression-free Survival in the Intent-to-treat Population

    To compare PSA progression-free survival in each of the experimental arms (LHRH analogue + apalutamide; LHRH analogue + apalutamide +abiraterone acetate) versus the control arm (LHRH analogue) among all randomized patients (intent-to-treat population). PSA progression-free survival (PSA PFS) is defined as time from date of randomization to date of PSA progression or death, whichever occurs first. PSA progression during the 52-week treatment period defined as a rising PSA confirmed on repeat measurement and at least 25% and 2 ng/mL above nadir or baseline, whichever is lower. PSA progression during the follow up phase (post-52 weeks) is defined as the first date of serum PSA \> 0.2 ng/mL, confirmed by repeat measurement at least 2 weeks later.

    Time frame: 36 months

Secondary outcomes

  1. PSA Progression-free Survival in the Testosterone-evaluable Population

    Compare PSA progression-free survival in testosterone-evaluable population in each experimental arm versus the control arm. Testosterone-evaluable population includes all patients who achieve serum testosterone recovery to \> 50 ng/dL with subsequent PSA measurements sufficient for evaluation

    Time frame: 36 months

  2. PSA Progression-free Survival in Both the Intent-to-treat and Testosterone-evaluable Populations

    To compare the 36-month PSA progression-free survival rate in each experimental arm versus the control arm in both the intent-to-treat and testosterone-evaluable populations.

    Time frame: 36 months

  3. Serum Testosterone

    To compare the time to recovery of serum testosterone to greater than 50 ng/dL in each experimental arm versus the control arm.

    Time frame: 12 months

  4. Time to Castration Resistance

    To compare the time to castration resistance in each experimental arm versus the control arm. The time to castration resistance will be defined as the first date of PSA increase \> 25% and more than 2 ng/mL above nadir with concomitant serum testosterone \< 50 ng/dL.

    Time frame: 6 years

  5. Metastasis-Free Survival

    To compare metastasis-free survival in each experimental arm versus the control arm.

    Time frame: 6 years

  6. Overall Survival

    To compare overall survival in each experimental arm versus the control arm.

    Time frame: 6 years

  7. Number of Participants With Treatment-related Grade 3+ Adverse Events as Assessed by CTCAE v4.0

    To characterize the safety profile in each treatment arm

    Time frame: 6 years

  8. Quality of Life Expanded Prostate Cancer Index Composite (EPIC)

    Expanded Prostate Cancer Index Composite-26 (EPIC-26), a prostate cancer-specific health-related quality of life instrument. The following domain scores are reported: Bowel (bowel function and bother), Hormonal (hormonal function and bother), Sexual (sexual function and bother), Urinary Incontinence (urinary leakage and associated bother), and Urinary Irritative/Obstructive (urinary frequency, urgency, weak stream, and associated bother). For each domain, scores are transformed to a standardized scale ranging from 0 to 100. A score of 0 represents the worst health-related quality of life and a score of 100 represents the best health-related quality of life for that domain. Higher scores indicate better function, fewer symptoms, and less bother. Domain scores are calculated according to the EPIC-26 scoring algorithm by combining responses from items within each domain and transforming the result to a 0-100 scale.

    Time frame: 24 months

  9. Quality of Life Hot Flash Related Daily Interference Scale (HFRDIS)

    Hot Flash Related Daily Interference Scale (HFRDIS). Possible range: 0 to 100, with higher scores being worse.

    Time frame: 24 months

  10. Quality of Life EQ-5D-5L

    EQ-5D-5L Utility based on United States value set. Possible range: -0.573 to 1.000, with higher scores being better. EQ-5D-5L Visual Analog Scale. Possible range: 0 to 100, with higher scores being better.

    Time frame: 24 months

  11. Quality of Life PROMIS Fatigue 8a

    PROMIS Fatigue 8a T-score. Possible range: 33.1 to 77.8, with higher scores being worse.

    Time frame: 24 months

  12. Quality-adjusted PSA Progression-free Survival

    To compare the restricted mean quality-adjusted PSA progression-free survival (PSA progression-free survival multiplied by EQ-5D-5L utility score) through 36 months in each experimental arm versus the control arm.

    Time frame: 36 months

07

Results

Posted Nov 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Started166168169
Completed140156148
Not completed261221

Outcome measures

PrimaryPSA Progression-free Survival in the Intent-to-treat Population

To compare PSA progression-free survival in each of the experimental arms (LHRH analogue + apalutamide; LHRH analogue + apalutamide +abiraterone acetate) versus the control arm (LHRH analogue) among all randomized patients (intent-to-treat population). PSA progression-free survival (PSA PFS) is defined as time from date of randomization to date of PSA progression or death, whichever occurs first. PSA progression during the 52-week treatment period defined as a rising PSA confirmed on repeat measurement and at least 25% and 2 ng/mL above nadir or baseline, whichever is lower. PSA progression during the follow up phase (post-52 weeks) is defined as the first date of serum PSA \> 0.2 ng/mL, confirmed by repeat measurement at least 2 weeks later.

Time frame:
36 months
Reported as:
Median · Months
PSA Progression-free Survival in the Intent-to-treat Population
MonthsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
PSA Progression-free Survival in the Intent-to-treat Population20.4 (18.9 to 22.5)24.7 (23.3 to 26.9)27.2 (25.5 to 30.5)
SecondaryPSA Progression-free Survival in the Testosterone-evaluable Population

Compare PSA progression-free survival in testosterone-evaluable population in each experimental arm versus the control arm. Testosterone-evaluable population includes all patients who achieve serum testosterone recovery to \> 50 ng/dL with subsequent PSA measurements sufficient for evaluation

Time frame:
36 months
Reported as:
Median · Months
PSA Progression-free Survival in the Testosterone-evaluable Population
MonthsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
PSA Progression-free Survival in the Testosterone-evaluable Population22.1 (20.4 to 25.9)25.0 (23.7 to 27.6)27.1 (25.4 to 30.9)
SecondaryPSA Progression-free Survival in Both the Intent-to-treat and Testosterone-evaluable Populations

To compare the 36-month PSA progression-free survival rate in each experimental arm versus the control arm in both the intent-to-treat and testosterone-evaluable populations.

Time frame:
36 months
Reported as:
Median · Percentage of Participants
PSA Progression-free Survival in Both the Intent-to-treat and Testosterone-evaluable Populations
Percentage of ParticipantsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Intent-to-treat17.2 (11.8 to 24.9)25.9 (19.8 to 34.0)32.1 (25.4 to 40.6)
Testosterone-evaluable19.8 (13.5 to 29.0)26.1 (19.7 to 34.5)32.7 (25.7 to 41.6)
SecondarySerum Testosterone

To compare the time to recovery of serum testosterone to greater than 50 ng/dL in each experimental arm versus the control arm.

Time frame:
12 months
Reported as:
Median · Months
Serum Testosterone
MonthsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Serum Testosterone4.0 (3.7 to 4.8)3.9 (3.7 to 4.9)4.7 (4.0 to 5.0)
SecondaryTime to Castration Resistance

To compare the time to castration resistance in each experimental arm versus the control arm. The time to castration resistance will be defined as the first date of PSA increase \> 25% and more than 2 ng/mL above nadir with concomitant serum testosterone \< 50 ng/dL.

Time frame:
6 years
Reported as:
Median · Months
Time to Castration Resistance
MonthsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Time to Castration ResistanceNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryMetastasis-Free Survival

To compare metastasis-free survival in each experimental arm versus the control arm.

Time frame:
6 years
Reported as:
Median · Months
Metastasis-Free Survival
MonthsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Metastasis-Free Survival58.5 (44.2 to NA)56.3 (50.9 to NA)55.5 (51.1 to 76.6)
SecondaryOverall Survival

To compare overall survival in each experimental arm versus the control arm.

Time frame:
6 years
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Overall Survival148155158
SecondaryNumber of Participants With Treatment-related Grade 3+ Adverse Events as Assessed by CTCAE v4.0

To characterize the safety profile in each treatment arm

Time frame:
6 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Grade 3+ Adverse Events as Assessed by CTCAE v4.0
ParticipantsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Number of Participants With Treatment-related Grade 3+ Adverse Events as Assessed by CTCAE v4.0354368
SecondaryQuality of Life Expanded Prostate Cancer Index Composite (EPIC)

Expanded Prostate Cancer Index Composite-26 (EPIC-26), a prostate cancer-specific health-related quality of life instrument. The following domain scores are reported: Bowel (bowel function and bother), Hormonal (hormonal function and bother), Sexual (sexual function and bother), Urinary Incontinence (urinary leakage and associated bother), and Urinary Irritative/Obstructive (urinary frequency, urgency, weak stream, and associated bother). For each domain, scores are transformed to a standardized scale ranging from 0 to 100. A score of 0 represents the worst health-related quality of life and a score of 100 represents the best health-related quality of life for that domain. Higher scores indicate better function, fewer symptoms, and less bother. Domain scores are calculated according to the EPIC-26 scoring algorithm by combining responses from items within each domain and transforming the result to a 0-100 scale.

Time frame:
24 months
Reported as:
Mean · score on a scale
Quality of Life Expanded Prostate Cancer Index Composite (EPIC)
score on a scaleArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Bowel: Cycle 1 Day 192.1977 ± 0.872595.5881 ± .857792.9830 ± 0.8462
Bowel: Cycle 7 Day 192.3285 ± 0.990192.6867 ± 0.944192.9257 ± 0.9807
Bowel: End Of Treatment91.8436 ± 0.906893.2766 ± 0.890893.7399 ± 0.8958
Bowel: 12 Month Followup91.8805 ± 1.708094.0190 ± 1.318793.6232 ± 1.2485
Hormonal: Cycle 1 Day 190.8704 ± 0.880192.6966 ± 0.860092.4077 ± 0.8541
Hormonal: Cycle 7 Day 171.9340 ± 1.587872.4698 ± 1.498273.7223 ± 1.5470
Hormonal: End Of Treatment70.7970 ± 1.634869.3380 ± 1.555170.8667 ± 1.5890
Hormonal: !2 Month Followup77.0712 ± 2.708582.7995 ± 2.050983.3635 ± 1.9303
Sexual: Cycle 1 Day 130.6812 ± 2.275930.9818 ± 2.205129.1073 ± 2.2113
Sexual: Cycle 7 Day 118.1788 ± 1.564716.9067 ± 1.483014.6919 ± 1.5521
Sexual: End Of Treatment15.0649 ± 1.396015.2038 ± 1.336913.8752 ± 1.3487
Sexual: !2 Month Followup22.7586 ± 3.316928.4695 ± 2.529222.4491 ± 2.4623
Urinary Incontinence: Cycle 1 Day 163.3541 ± 2.161868.9151 ± 2.119767.7220 ± 2.1106
Urinary Incontinence: Cycle 7 Day 157.1646 ± 2.234963.8409 ± 2.168963.8077 ± 2.2102
Urinary Incontinence: End Of Treatment54.7990 ± 2.308159.5621 ± 2.249062.3346 ± 2.2668
Urinary Incontinence: 12 Month Followup62.5641 ± 3.460966.0652 ± 2.723566.0887 ± 2.6035
Urinary Irritative/Obstructive: Cycle 1 Day 188.3962 ± 1.087790.0618 ± 1.065389.7642 ± 1.0557
Urinary Irritative/Obstructive: Cycle 7 Day 185.6048 ± 1.102288.4706 ± 1.056189.5044 ± 1.0865
Urinary Irritative/Obstructive: End Of Treatment85.6995 ± 1.214087.3553 ± 1.153387.6484 ± 1.1880
Urinary Irritative/Obstructive: 12 Month Followup87.8178 ± 2.437186.8772 ± 1.818287.4965 ± 1.6848
SecondaryQuality of Life Hot Flash Related Daily Interference Scale (HFRDIS)

Hot Flash Related Daily Interference Scale (HFRDIS). Possible range: 0 to 100, with higher scores being worse.

Time frame:
24 months
Reported as:
Mean · score on a scale
Quality of Life Hot Flash Related Daily Interference Scale (HFRDIS)
score on a scaleArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Cycle 1 Day 11.3664 ± 0.57521.8130 ± 0.54940.9377 ± 0.5464
Cycle 7 Day 114.4733 ± 1.732316.9856 ± 1.667616.0595 ± 1.7506
End Of Treatment14.2634 ± 1.804215.9672 ± 1.707215.2892 ± 1.7465
12 Month Followup6.7725 ± 2.26146.2001 ± 1.67316.1189 ± 1.6167
SecondaryQuality of Life EQ-5D-5L

EQ-5D-5L Utility based on United States value set. Possible range: -0.573 to 1.000, with higher scores being better. EQ-5D-5L Visual Analog Scale. Possible range: 0 to 100, with higher scores being better.

Time frame:
24 months
Reported as:
Mean · score on a scale
Quality of Life EQ-5D-5L
score on a scaleArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Visual Analog Scale: Cycle 1 Day 182.0063 ± 1.099883.9279 ± 1.079582.8025 ± 1.0533
Visual Analog Scale: Cycle 7 Day 180.0568 ± 1.338880.5834 ± 1.329880.5332 ± 1.3367
Visual Analog Scale: End Of Treatment79.1598 ± 1.231680.7935 ± 1.194680.5343 ± 1.1969
Visual Analog Scale:12 Month Followup82.0226 ± 2.134281.2757 ± 1.602882.5706 ± 1.5280
Utility Score: Cycle 1 Day 10.8821 ± 0.0082980.9091 ± 0.0080630.9027 ± 0.008105
Utility Score: Cycle 7 Day 10.8783 ± 0.0094120.8969 ± 0.0090020.8935 ± 0.009346
Utility Score: End Of Treatment0.8711 ± 0.0096890.8934 ± 0.0092970.9000 ± 0.009503
Utility Score: 12 Month Followup0.8623 ± 0.016490.8890 ± 0.012910.8979 ± 0.01229
SecondaryQuality of Life PROMIS Fatigue 8a

PROMIS Fatigue 8a T-score. Possible range: 33.1 to 77.8, with higher scores being worse.

Time frame:
24 months
Reported as:
Mean · score on a scale
Quality of Life PROMIS Fatigue 8a
score on a scaleArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Cycle 1 Day 144.5051 ± 0.747343.1027 ± 0.729543.4506 ± 0.7308
Cycle 7 Day 149.7267 ± 0.873350.4765 ± 0.834050.6559 ± 0.8654
End Of Treatment51.4744 ± 0.939452.1293 ± 0.902052.1751 ± 0.9169
12 Month Followup48.4949 ± 1.646647.6405 ± 1.243246.8446 ± 1.2010
SecondaryQuality-adjusted PSA Progression-free Survival

To compare the restricted mean quality-adjusted PSA progression-free survival (PSA progression-free survival multiplied by EQ-5D-5L utility score) through 36 months in each experimental arm versus the control arm.

Time frame:
36 months
Reported as:
Mean · years
Quality-adjusted PSA Progression-free Survival
yearsArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Quality-adjusted PSA Progression-free Survival1.66 (1.56 to 1.76)1.97 (1.88 to 2.07)2.07 (1.97 to 2.17)

Adverse events

Collected over Up to 6 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide18/166 (10.8%)14/166 (8.4%)154/166 (92.8%)
Arm B: Degarelix/Apalutamide13/168 (7.7%)15/168 (8.9%)167/168 (99.4%)
Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone11/169 (6.5%)23/169 (13.6%)163/169 (96.4%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
HypertensionVascular disorders0/1661/1686/169
SepsisInfections and infestations0/1660/1684/169
FallInjury, poisoning and procedural complications3/1660/1680/169
Lung infectionInfections and infestations0/1660/1683/169
FractureInjury, poisoning and procedural complications2/1660/1681/169
Neoplasms benign, mal, uncpec - Oth specNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1660/1681/169
Gen disord and admin site conds-Oth specGeneral disorders0/1662/1680/169
Infections and infestations - Oth specInfections and infestations0/1662/1681/169
Non-cardiac chest painGeneral disorders0/1660/1682/169
StrokeNervous system disorders0/1660/1682/169
Most frequent other events
Showing 10 of 271
Most frequent other events
EventArm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/Prednisone
Hot flashesVascular disorders136/166147/168142/169
FatigueGeneral disorders91/166106/168105/169
HypertensionVascular disorders42/16654/16865/169
Injection site reactionGeneral disorders63/16664/16850/169
AnemiaBlood and lymphatic system disorders35/16647/16831/169
InsomniaPsychiatric disorders32/16638/16840/169
Rash maculo-papularSkin and subcutaneous tissue disorders9/16638/16830/169
HyperglycemiaMetabolism and nutrition disorders16/16626/16838/169
HeadacheNervous system disorders19/16632/16838/169
DiarrheaGastrointestinal disorders18/16636/16828/169

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
Median67.2 (60.5 to 71.1)66.0 (60.7 to 70.3)67.3 (62.4 to 71.3)66.7 (61.2 to 71.0)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
Female0000
Male166168169503
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
Hispanic or Latino1010727
Not Hispanic or Latino151153156460
Unknown or Not Reported55616
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
American Indian or Alaska Native1023
Asian301013
Native Hawaiian or Other Pacific Islander1012
Black or African American7131232
White142145136423
More than one race0000
Unknown or Not Reported1210830
Gleason Score Baseline
Gleason Score Baseline(Participants)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
6-7102102105309
815221956
9-10494344136
Missing0112
Prostate-Specific Antigen (PSA) at study entry
Prostate-Specific Antigen (PSA) at study entry(ng/mL)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
Median1.7 (1.0 to 3.2)1.8 (1.0 to 3.5)1.8 (1.0 to 4.2)1.8 (1.0 to 3.6)
PSA Doubling Time
PSA Doubling Time(Participants)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
3 to 9 months123125125373
Less than 3 months434344130
N stage
N stage(Participants)Arm A: Degarelix Monotherapy OR Leuprolide/BicalutamideArm B: Degarelix/ApalutamideArm C: Degarelix/Apalutamide/Abiraterone/PrednisoneTotal
N0127130130387
N124252372
NX / Missing15131644

5 further baseline measures are reported on the registry.

08

Study locations

69 sites
  • The Mayo Clinic - Phoenix
    Phoenix, Arizona 85054, United States
  • Sharp Memorial Hospital
    Chula Vista, California 91911, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Palo Alto Medical Foundation
    Fremont, California 94538, United States
  • VA Central California Health Care System
    Fresno, California 93703, United States
  • Sharp Memorial Hospital
    La Mesa, California 91942, United States
  • Palo Alto Medical Foundation
    Mountain View, California 94040, United States
  • Palo Alto Medical Foundation
    Palo Alto, California 94301, United States
  • University of California San Diego - Moores Cancer Center
    San Diego, California 92093, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Palo Alto Medical Foundation
    Santa Cruz, California 95065, United States
  • Adventist Health St. Helena/St. Helena Hospital/Martin O'Neil Cancer Center
    St. Helena, California 94574, United States
  • Palo Alto Medical Foundation
    Sunnyvale, California 94086, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20007, United States
  • University of Hawaii Cancer Center
    Honolulu, Hawaii 96813, United States
  • Pali Momi Medical Center
    ‘Aiea, Hawaii 96701, United States
  • Rush University Medical Center
    Chicago, Illinois 606012, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • Northshore University Health System
    Evanston, Illinois 60201, United States
  • Loyola University
    Maywood, Illinois 60153, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Eastern Maine Medical Center
    Brewer, Maine 04412, United States
  • New England Cancer Specialists
    Kennebunk, Maine 04043, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • New England Cancer Specialists
    Topsham, Maine 04086, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Milford, Massachusetts 01757, United States
  • Dana Farber Cancer Institute
    South Weymouth, Massachusetts 02190, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Metro Minnesota Community Oncology Research Consortium
    Saint Louis Park, Minnesota 55416, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • New Hampshire Oncology & Hematology
    Concord, New Hampshire 03301, United States
  • New Hampshire Oncology & Hematology
    Hooksett, New Hampshire 03106, United States
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Cancer Center
    Middletown, New Jersey 07748, United States
  • Atlantic Health System/Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87109, United States
  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87131, United States
  • Memorial Medical Center- Cancer Center
    Las Cruces, New Mexico 88011, United States
  • Christus St. Vincent's Regional Cancer Center
    Santa Fe, New Mexico 87505, United States
  • VA Western New York
    Buffalo, New York 14215, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center
    Harrison, New York 11533, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical Ctr - New York Presbyterian Hospital
    New York, New York 10065, United States
  • Montefiore Medical Center
    New York, New York 10461, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • University of North Carolina Hospital
    Chapel Hill, North Carolina 27514, United States
  • Novant Health Presbyterian Medical Center
    Charlotte, North Carolina 28204, United States
  • VA Salisbury
    Salisbury, North Carolina 28144, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Dayton Physicians Miami Valley South
    Centerville, Ohio 45459, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • The Toledo Clinic
    Toledo, Ohio 43623, United States
  • Oklahoma Cancer Specialists and Research Institute
    Tulsa, Oklahoma 74146, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Spartanburg Medical Center/Gibbs Cancer Center
    Spartanburg, South Carolina 29303, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Marshfield Clinic Cancer Center
    Marshfield, Wisconsin 54449, United States
  • Froedtert Hospital/Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. PubMed 25559415 ↗
  • Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004 Jan;171(1):210-4. doi: 10.1097/01.ju.0000100980.13364.a6. PubMed 14665878 ↗
  • Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17. PubMed 26996659 ↗
  • Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005 Feb 1;23(4):826-31. doi: 10.1200/JCO.2005.02.111. PubMed 15681527 ↗
  • Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015 Jan 7;5:7654. doi: 10.1038/srep07654. PubMed 25563505 ↗
  • Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D. The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas. 2010;11(3):304-14. PubMed 20847477 ↗
  • Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29. PubMed 38421252 ↗
  • Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ; EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 1;42(10):1114-1123. doi: 10.1200/JCO.23.01157. Epub 2024 Jan 23. PubMed 38261983 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jun 2025, 99 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's 99 months is close to that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 4, 2017
StartActual
Mar 6, 2017
Primary completionActual
Jun 25, 2025
CompletionActual
Jun 25, 2025
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Enrollment
504→503
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPSA progressionProgression-free survivalSurvival in the intentIntent-to-treat populationPopulationTime frame: 36 months
Nov 9, 2026
Secondary outcomes
10 edited
What changed in the outcomes
  • EditedPSA progressionProgression-free survivalSurvival in the testosteroneTestosterone-evaluable populationPopulationTime frame: 36 months
  • EditedPSA progressionProgression-free survivalSurvival in bothBoth the intentIntent-to-treat and testosteroneTestosterone-evaluable populationsPopulationsTime frame: 36 months
  • EditedSerum testosteroneTestosteroneTime frame: 12 months
  • EditedTime to castration resistanceCastration ResistanceTime frame: 6 years
  • EditedNumber of participants with treatmentParticipants With Treatment-related adverse eventsGrade 3+ Adverse Events as assessedAssessed by CTCAE v4.0Time frame: 6 years
  • EditedQuality of lifeLife Expanded Prostate Cancer Index Composite (EPIC)Time frame: 72 months → 24 months
  • EditedQuality of lifeLife Hot Flash Related Daily Interference Scale (HFRDIS)Time frame: 72 months → 24 months
  • EditedQuality of lifeLife EQ-5D-5LTime frame: 72 months → 24 months
  • EditedQuality of lifeLife PROMIS Fatigue 8aTime frame: 72 months → 24 months
  • EditedQuality-adjusted survivalPSA Progression-free SurvivalTime frame: 72 months → 36 months
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    Enrollment 504→503
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPSA progressionProgression-free survivalSurvival in the intentIntent-to-treat populationPopulationTime frame: 36 months
    Secondary outcomes 10 edited
    What changed in the outcomes
    • EditedPSA progressionProgression-free survivalSurvival in the testosteroneTestosterone-evaluable populationPopulationTime frame: 36 months
    • EditedPSA progressionProgression-free survivalSurvival in bothBoth the intentIntent-to-treat and testosteroneTestosterone-evaluable populationsPopulationsTime frame: 36 months
    • EditedSerum testosteroneTestosteroneTime frame: 12 months
    • EditedTime to castration resistanceCastration ResistanceTime frame: 6 years
    • EditedNumber of participants with treatmentParticipants With Treatment-related adverse eventsGrade 3+ Adverse Events as assessedAssessed by CTCAE v4.0Time frame: 6 years
    • EditedQuality of lifeLife Expanded Prostate Cancer Index Composite (EPIC)Time frame: 72 months → 24 months
    • EditedQuality of lifeLife Hot Flash Related Daily Interference Scale (HFRDIS)Time frame: 72 months → 24 months
    • EditedQuality of lifeLife EQ-5D-5LTime frame: 72 months → 24 months
    • EditedQuality of lifeLife PROMIS Fatigue 8aTime frame: 72 months → 24 months
    • EditedQuality-adjusted survivalPSA Progression-free SurvivalTime frame: 72 months → 36 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03009981
Lead sponsor
Alliance Foundation Trials, LLC.
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Mar 6, 2017
Primary completion
Jun 25, 2025
Completion
Jun 25, 2025
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Study contacts

Evanthia Evanthia Galanis, MD
principal investigator · Alliance Foundation Trials, LLC.
Rahul Aggarwal, MD
study chair · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion